Minoryx Therapeutics SL has closed a €51m financing, including Series C equity financing and complementary bank debt to commercialise X-ALD drug leriglitazone.
G7 Climate, Energy and Environment Ministers have announced a wide range of actions to tackle the triple global crisis of climate change, biodiversity loss and pollution".
An anti-idiotypic antibody (anti-ID Ab) can recognise and bind to the idiotypic center of another antibody. Anti-idiotype antibodies are widely used in therapeutic drug development, such as immunogenicity assessments, pharmacokinetic/pharmacodynamics (PK/PD) studies, and vaccine development.
Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein set to eliminate solid tumours.
COVID-19 is the acute pandemic, while antimicrobial resistance (AMR) is a silent, pandemic. New data makes the AMR pandemic visible, with the first global study of AMR estimating that 1.27 million people die from AMR every year, making AMR the 12th-leading cause of death globally.
Hamburg-based CRO Evotec SE has inked a drug development partnership with Spanish Almirall SA in dematology.
Avantium NV will get a €3m EU funding for a feasibility study of the electrochemical conversion of CO2 to consumer products.
Biocatalysis expert Enzymaster (Germany, China, Singapore) has cashed in $45m to expand its production capacity of engineered biosynthetic enzymes.
The EU Commission has launched its final consultation on the deregulation of new breeding techniques in agriculture.
Hamburg-headquartered Evotec SE has extended and expanded its three-year-old partnership with Bristol Myers Squibb in targeted protein degradation ("molecular glue degraders") for an additional eight years.
Bristol Myers Squibb brings in a huge library of E3 ligase modulators. Under the terms of the agreement, both parties will leverage all of Evotecs appropriate platforms as well as AI/ML-based drug discovery.
Under the new agreement, Evotec cashes in an upfront payment of $200m and is eglible to obtain up to $5bn in milestone payments and tiered royalties on product sales.